GLP-1 receptor agonists
-
healthReframing HFpEF as a Systemic Inflammatory Disorder
New models suggest heart failure with preserved ejection fraction is driven by a vicious inflammatory cycle involving the heart, liver, and pancreas, demanding an interdisciplinary treatment approach.
-
healthGLP-1 Drugs Show Promise for Joint and Bone Health Beyond Weight Loss
New research highlights how GLP-1 receptor agonists may protect cartilage, bone, and muscle, offering therapeutic potential for osteoarthritis and back pain.
-
healthGLP-1 Therapies: Bone, Joint & Muscle Effects Beyond Weight Loss
Experts examine the complex musculoskeletal impact of GLP-1 drugs, from bone density to sarcopenia, at the ESCEO symposium.
-
healthGLP-1 Drugs Cut Heart Damage in Cancer Patients
Real-world study finds GLP-1 agonists reduce cardiac dysfunction from cancer therapy, with strongest benefits in key subgroups.
-
healthNew Study Reveals Safer Diabetes Drugs for Seniors
Real-world data identifies safer antihyperglycemic agents for older adults with type 2 diabetes, reducing risks of hypoglycemia and other serious complications.
-
healthGLP-1 Drugs Show Safety, Better Outcomes in Pancreatitis Cases
Real-world data from 740,000+ Type 2 diabetes patients shows GLP-1 receptor agonists don't increase pancreatitis risk and reduce complications.
-
healthObesity Drives Advanced Liver Disease-New Treatments Emerge
Obesity is now a leading cause of cirrhosis and liver cancer. Weight loss and GLP-1 drugs show promise in halting progression.
-
healthGLP-1 Drugs Linked to Lower Risk of Worsening Anxiety and Depression
Semaglutide and liraglutide show significant mental health benefits in patients with anxiety or depression, per large-scale Swedish study.